Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2369
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib ; volume:16 ; number:1 ; day:1 ; month:8 ; year:2015 ; pages:1-5 ; date:12.2015
BMC nephrology ; 16, Heft 1 (1.8.2015), 1-5, 12.2015
- Urheber
-
Rajasekaran, Arun
- Beteiligte Personen und Organisationen
-
Ngo, Thuy-Trang
Abdelrahim, Maen
Glass, William
Podoll, Amber
Verstovsek, Srdan
Abudayyeh, Ala
SpringerLink (Online service)
- DOI
-
10.1186/s12882-015-0121-6
- URN
-
urn:nbn:de:1111-201611058555
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rajasekaran, Arun
- Ngo, Thuy-Trang
- Abdelrahim, Maen
- Glass, William
- Podoll, Amber
- Verstovsek, Srdan
- Abudayyeh, Ala
- SpringerLink (Online service)
Ähnliche Objekte (12)
Management of myelofibrosis after ruxolitinib failure
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
Splenic Marginal Zone Lymphoma with Prominent Myelofibrosis Mimicking Triple-Negative Primary Myelofibrosis
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
Management of myelofibrosis after ruxolitinib failure
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
Splenic Marginal Zone Lymphoma with Prominent Myelofibrosis Mimicking Triple-Negative Primary Myelofibrosis
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
Management of myelofibrosis after ruxolitinib failure
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
Splenic Marginal Zone Lymphoma with Prominent Myelofibrosis Mimicking Triple-Negative Primary Myelofibrosis
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes